Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07434063

Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection

Sponsor: Hebei Medical University Fourth Hospital

View on ClinicalTrials.gov

Summary

This study is a multicenter, observational real-world study, aiming to observe and evaluate the efficacy and safety of prophylactic application of Mecapegfilgrastim Injection in tumor patients after radiotherapy/chemotherapy/immunotherapy in the real world to prevent neutropenia.The subjects who met the inclusion criteria of the protocol were defined as those who needed radiotherapy/chemotherapy/immunotherapy after being diagnosed with solid malignant tumors. The researchers believed that the subjects needed to use Mecapegfilgrastim Injection for primary/secondary prevention after receiving tumor treatment.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2025-06-18

Completion Date

2027-06-30

Last Updated

2026-02-25

Healthy Volunteers

No

Conditions

Interventions

DRUG

Mecapegfilgrastim Injection

Use it 24 hours after the end of each treatment cycle at a fixed dose of 6 mg or 100μg/kg each time

Locations (1)

HebeiMuFH

Shijiazhuang, Hebei, China